ACR Convergence 2022
Summaries from ACR Convergence 2022, held from November 10 – 14, 2022.
Guselkumab sustains improvements in work productivity and daily activity in patients with active psoriatic arthritis
Presenter: Jeffrey Curtis, MD, University of Alabama at Birmingham, Birmingham, AL
Guselkumab-treated patients with psoriatic arthritis show sustained improvements in work productivity and daily activity through 2 years.
Short composite measures identify disease activity in psoriatic arthritis
Presenter: William Tillett, PhD, MBChB, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Abbreviated visual analogue scales can accurately assess disease activity in psoriatic arthritis.
Guselkumab provides consistent long-term efficacy in psoriatic arthritis
Presenter: Iain McInnes, PhD, FRCP, University of Glasgow, Glasgow, United Kingdom
Guselkumab significantly improves the signs and symptoms of psoriatic arthritis across all baseline patient subgroups, including those with highly active disease, regardless of the dosing regimen for up to 2 years.
Peripheral blood methylation may become useful biomarker in knee osteoarthritis
Presenter: Matlock Jeffries, MD, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States
An analysis of peripheral blood epigenetic patterns may predict which patients with knee osteoarthritis are likely to progress.
Risk assessment score guides screening of systemic sclerosis-associated interstitial lung disease
Presenter: Cosimo Bruni, MD, PhD, University of Florence, Florence, Italy
Researchers develop a risk assessment scoring system to guide the use of high-resolution computed tomography to detect interstitial lung disease in patients diagnosed with systemic sclerosis.
Guselkumab improves psoriatic arthritis disease activity in multiple composite scores
Presenter: Laure Gossec, MD, PhD, Sorbonne Universite, Paris, France
Guselkumab provides substantial improvement in disease activity across multiple composite scores for patients with active psoriatic arthritis (PsA) who were refractory to tumor necrosis factor (TNF) inhibitor therapy.
Guselkumab enhances responses in patients with psoriatic arthritis and active axial involvement
Presenter: Philip Mease, MD, Swedish Medical Center/Providence-St Joseph Health, Seattle, WA
Patients with psoriatic arthritis and active axial involvement treated with guselkumab show significant and clinically meaningful improvements in disease activity after 2 years.
Combination therapy with an NSAID and TNF inhibitor only slightly slows spinal progression of radiographic axial spondyloarthritis
Presenter: Fabian Proft, MD, Department of Gastroenterology, Infectious Disease and Rheumatology, Charité — Universitätsmedizin Berlin, Berlin, Germany
This study found no significant benefit from combined treatment with an NSAID and a TNF-inhibitor in reducing spinal progression in patients with radiographic axial spondyloarthritis; however, this therapy may have efficacy in some high-risk patients.
Pegloticase plus methotrexate increases response rates in uncontrolled gout cases
Presenter: John Botson, MD, Orthopedic Physicians Alaska, Anchorage, AK
A combination of pegloticase and methotrexate continues to sustain high rates of urate-lowering response in patients with uncontrolled gout at 12 months